A
Alcista
Alcista · 25%ANAB
$53.20
Precio del escenario
$47.940
+2.646 (+5.52%)Al cierre
Loading chart…
- Máximo
- 48.475
- Apertura
- 45.480
- Precio medio ponderado por volumen
- 47.30
- Volumen
- 664.46K
- Capitalización
- 677.50M
- Mínimo
- 45.480
- Importe
- 31.43M
- EV/EBITDA, TTM
- 15.96
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Análisis de IA of AnaptysBio, Inc. (ANAB)
MantenerAnaptysBio is currently not a strong buy due to its current price of $46.61 being below the recent analyst price targets, which range from $60 to $90. The RSI is at 42.212, indicating it is nearing oversold territory, but the recent earnings report showed a significant net income of $183.88 million driven by a tax benefit, suggesting potential for recovery. However, the risk remains high with a forward P/E of 21.0084, indicating that the stock may be overvalued based on future earnings expectations, especially considering the volatility in its earnings and the recent litigation outcomes.
Recomendaciones de analistas (8)
+54.63% de potencial alcista
Comprar
8 Comprar
0 Mantener
0 Vender
Actual: 47.94
Mínimo
50.00
Promedio
74.13
Máximo
140.00
JPMorgan
Sobreponderar
$60
2026-09-30
JPMorgan
2026-09-30
Precio objetivo
$60
Sobreponderar
TD Cowen
Comprar
$70
2026-08-25
TD Cowen
2026-08-25
Precio objetivo
$70
Comprar
Leerink
Superar al mercado
$90
2026-05-15
Leerink
2026-05-15
Precio objetivo
$90
Superar al mercado
UBS
Comprar
$76
2026-05-13
UBS
2026-05-13
Precio objetivo
$76
Comprar
Barclays
Sobreponderar
$75
2026-05-13
Barclays
2026-05-13
Precio objetivo
$75
Sobreponderar
Métricas de valoración
El PER previsto actual de AnaptysBio, Inc. (ANAB) es 21.01, frente a su media de 5 años de -3.36.
Escenarios de precio de Alphio AI para ANAB
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ANAB en cartera
Cronología de eventos
Noticias
8.510-19NewsfilterFDA Approves Jemperli for Advanced Rectal Cancer Treatment
9.509-22NASDAQ.COMAnaptysBio Reports Significant Q2 Profit Growth Driven by Tax Benefits
9.505-12seekingalphaAnaptysBio Q1 Earnings Report Analysis
- 5.005-11Newsfilter
AnaptysBio Strengthens Leadership Team and Board
9.004-28PRnewswireVanda Pharmaceuticals Publishes Imsidolimab Research Findings
Preguntas frecuentes sobre ANAB, respondidas por Alphio AI
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AnaptysBio is currently not a strong buy due to its current price of $46.61 being below the recent analyst price targets, which range from $60 to $90. The RSI is at 42.212, indicating it is nearing oversold territory, but the recent earnings report showed a significant net income of $183.88 million driven by a tax benefit, suggesting potential for recovery. However, the risk remains high with a forward P/E of 21.0084, indicating that the stock may be overvalued based on future earnings expectations, especially considering the volatility in its earnings and the recent litigation outcomes.
8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.